Background/Aims: We aimed to explore whether ganoderma lucidum polysaccharide (GLP) exhibits antitumor effect on cervical cancer cells. Methods and Results: Different concentration of GLP was used to treat cervical cell. The data from cell counting kit-8 assay proved that the optimal working concentration and time of GLP were 200 µg/mL and treated for 48 h. The transwell assay demonstrated that GLP could attenuate the invasion and migration abilities of cervical cancer cells. Moreover, flow cytometry illustrated that GLP could promote the apoptosis of cervical cancer cells and limit the cycle of cervical cancer cells. Western blot assay discovered that the expression of proapoptosis proteins including Bax, Cleaved Caspases 3 and 9 increased and the antiapoptosis protein Bcl-2 decreased after treated with GLP. Moreover, we found that the expression of E-cadherin was increased, and N-cadherin, Vimentin, and Slug were decreased. Meanwhile, the expression of phosphorylated-JAK and phosphorylated-STAT5 was also decreased in cervical cancer cells treated by GLP, suggesting the inhibitory effect on JAK/STAT5 pathways. Conclusions: All of these data illustrated that GLP could alleviate the activity and aggressiveness, block the cell cycle, and promote the apoptosis of cervical cancer cells, which were possible via inhibiting epithelial-mesenchymal and JAK/STAT5 pathways.

Keywords:
Ganoderma lucidum polysaccharide, C-33A, HeLa, Epithelial-mesenchymal, JAK/STAT5
1.
Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: screening, diagnosis and staging.
J BUON
. 2016 Mar-Apr;21(2):320–5.
2.
Singh KP, Verma N, Akhoon BA, Bhatt V, Gupta SK, Gupta SK, et al. Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains.
3 Biotech
. 2016 Jun;6(1):39.
3.
Bostofte E, Serup J. Urological complications of Okabayashi’s operation for cervical cancer.
Acta Obstet Gynecol Scand
. 1981;60(1):39–42.
4.
Vesterinen E, Kivinen S, Nieminen U. Cervical carcinoma complicated by malignant pericarditis.
Acta Obstet Gynecol Scand
. 1987;66(6):569–71.
5.
Zhu J, Xu J, Jiang LL, Huang JQ, Yan JY, Chen YW, et al. Improved antitumor activity of cisplatin combined with Ganoderma lucidum polysaccharides in U14 cervical carcinoma-bearing mice.
Kaohsiung J Med Sci
. 2019 Apr;35(4):222–9.
6.
Chhabra R. Cervical cancer stem cells: opportunities and challenges.
J Cancer Res Clin Oncol
. 2015 Nov;141(11):1889–97.
7.
Ai-Lati A, Liu S, Ji Z, Zhang H, Mao J. Structure and bioactivities of a polysaccharide isolated from Ganoderma lucidum in submerged fermentation.
Bioengineered
. 2017 Sep;8(5):565–71.
8.
Ma HT, Hsieh JF, Chen ST. Anti-diabetic effects of Ganoderma lucidum.
Phytochemistry
. 2015 Jun;114:109–13.
9.
Pan K, Jiang Q, Liu G, Miao X, Zhong D. Optimization extraction of Ganoderma lucidum polysaccharides and its immunity and antioxidant activities.
Int J Biol Macromol
. 2013 Apr;55:301–6.
10.
Kan Y, Chen T, Wu Y, Wu J, Wu J. Antioxidant activity of polysaccharide extracted from Ganoderma lucidum using response surface methodology.
Int J Biol Macromol
. 2015 Jan;72:151–7.
11.
Chang CJ, Chen YY, Lu CC, Lin CS, Martel J, Tsai SH, et al. Ganoderma lucidum stimulates NK cell cytotoxicity by inducing NKG2D/NCR activation and secretion of perforin and granulysin.
Innate Immun
. 2014 Apr;20(3):301–11.
12.
Zhou H, Liu G, Huang F, Wu X, Yang H. Improved production, purification and bioactivity of a polysaccharide from submerged cultured Ganoderma lucidum.
Arch Pharm Res
. 2014 Dec;37(12):1530–7.
13.
Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK. Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganoderma lucidum.
Acta Pharm
. 2011 Sep;61(3):335–42.
14.
Liu YJ, Shen J, Xia YM, Zhang J, Park HS. The polysaccharides from Ganoderma lucidum: are they always inhibitors on human hepatocarcinoma cells?
Carbohydr Polym
. 2012 Oct;90(3):1210–5.
15.
Zheng S, Jia Y, Zhao J, Wei Q, Liu Y. Ganoderma lucidum polysaccharides eradicates the blocking effect of fibrinogen on NK cytotoxicity against melanoma cells.
Oncol Lett
. 2012 Mar;3(3):613–6.
16.
Gill BS, Navgeet, Kumar S. Ganoderma lucidum targeting lung cancer signaling: A -review.
Tumour Biol
. 2017 Jun;39(6):1010428317707437.
17.
Lieu CW, Lee SS, Wang SY. The effect of Ganoderma lucidum on induction of differentiation in leukemic U937 cells.
Anticancer Res
. 1992 Jul-Aug;12(4):1211–5.
18.
Liang Z, Guo YT, Yi YJ, Wang RC, Hu QL, Xiong XY. Ganoderma lucidum polysaccharides target a Fas/caspase dependent pathway to induce apoptosis in human colon cancer cells.
Asian Pac J Cancer Prev
. 2014;15(9):3981–6.
19.
Wang J, Zhang Z, Li R, Mao F, Sun W, Chen J, et al. ADAM12 induces EMT and promotes cell migration, invasion and proliferation in pituitary adenomas via EGFR/ERK signaling pathway.
Biomed Pharmacother
. 2018 Jan;97:1066–77.
20.
Han ML, Zhao YF, Tan CH, Xiong YJ, Wang WJ, Wu F, et al. Cathepsin L upregulation-induced EMT phenotype is associated with the acquisition of cisplatin or paclitaxel resistance in A549 cells.
Acta Pharmacol Sin
. 2016 Dec;37(12):1606–22.
21.
Li RF, Wang GF. JAK/STAT5 signaling pathway inhibitor ruxolitinib reduces airway inflammation of neutrophilic asthma in mice model.
Eur Rev Med Pharmacol Sci
. 2018 Feb;22(3):835–43.
22.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
CA Cancer J Clin
. 2018 Nov;68(6):394–424.
23.
Chen LH, Lin ZB, Li WD. Ganoderma lucidum polysaccharides reduce methotrexate-induced small intestinal damage in mice via induction of epithelial cell proliferation and migration.
Acta Pharmacol Sin
. 2011 Dec;32(12):1505–12.
24.
Goossens S, Vandamme N, Van Vlierberghe P, Berx G. EMT transcription factors in cancer development re-evaluated: beyond EMT and MET.
Biochim Biophys Acta Rev Cancer
. 2017 Dec;1868(2):584–91.
25.
Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable actors of cancer progression.
Mol Oncol
. 2017 Jul;11(7):805–23.
26.
Ravikrishnan A, Ozdemir T, Bah M, Baskerville KA, Shah SI, Rajasekaran AK, et al. Regulation of Epithelial-to-Mesenchymal Transition Using Biomimetic Fibrous Scaffolds.
ACS Appl Mater Interfaces
. 2016 Jul;8(28):17915–26.
27.
Liu X, Feng R. Inhibition of epithelial to mesenchymal transition in metastatic breast carcinoma cells by c-Src suppression.
Acta Biochim Biophys Sin (Shanghai)
. 2010 Jul;42(7):496–501.
28.
Tsao SM, Hsu HY. Fucose-containing -fraction of Ling-Zhi enhances lipid rafts--dependent ubiquitination of TGFβ receptor degradation and attenuates breast cancer -tumorigenesis.
Sci Rep
. 2016 Nov;6(1):36563.
29.
Zhou F, Ge Z, Chen B. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Drug Des Devel Ther
. 2019 Apr;13:1117–25.
30.
Giordano G, Parcesepe P, D’Andrea MR, Coppola L, Di Raimo T, Remo A, et al. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
J Exp Clin Cancer Res
. 2019 Jan;38(1):28.
31.
Johnston AN, Bu W, Hein S, Garcia S, Camacho L, Xue L, et al. Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions.
Breast Cancer Res
. 2018 May;20(1):42.
32.
Lopez TV, Lappin TR, Maxwell P, Shi Z, Lopez-Marure R, Aguilar C, et al. Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells.
Int J Cancer
. 2011 Dec;129(11):2566–76.
© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.